Alzinova AB (publ) (ALZ.ST)
SEK 3.5
(0.0%)
SEK 3.5
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 270 Thousand SEK | -98.38% |
| 2022 | 16.63 Million SEK | -3.97% |
| 2021 | 17.32 Million SEK | 16.27% |
| 2020 | 14.89 Million SEK | 118.8% |
| 2019 | 6.8 Million SEK | -27.26% |
| 2018 | 9.36 Million SEK | 61.63% |
| 2017 | 5.79 Million SEK | 10.24% |
| 2016 | 5.25 Million SEK | 426.14% |
| 2015 | 998.38 Thousand SEK | 4.62% |
| 2014 | 954.33 Thousand SEK | 13.7% |
| 2013 | 839.37 Thousand SEK | -61.67% |
| 2012 | 2.18 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 30 Thousand SEK | -88.89% |
| 2024 Q2 | - SEK | -100.0% |
| 2023 Q2 | 6.01 Million SEK | 28.81% |
| 2023 Q4 | 270 Thousand SEK | -91.82% |
| 2023 Q1 | 4.67 Million SEK | 37.32% |
| 2023 FY | 270 Thousand SEK | -98.38% |
| 2023 Q3 | 3.3 Million SEK | -45.17% |
| 2022 Q4 | 3.4 Million SEK | 5.02% |
| 2022 Q3 | 3.24 Million SEK | 5.61% |
| 2022 FY | 16.63 Million SEK | -3.97% |
| 2022 Q2 | 3.06 Million SEK | -55.69% |
| 2022 Q1 | 6.92 Million SEK | 154.24% |
| 2021 Q3 | 2.36 Million SEK | -55.11% |
| 2021 FY | 17.32 Million SEK | 16.27% |
| 2021 Q1 | 6.95 Million SEK | 91.73% |
| 2021 Q2 | 5.27 Million SEK | -24.25% |
| 2021 Q4 | 2.72 Million SEK | 15.06% |
| 2020 Q2 | 2.14 Million SEK | -64.91% |
| 2020 FY | 14.89 Million SEK | 118.8% |
| 2020 Q4 | 3.63 Million SEK | 19.98% |
| 2020 Q3 | 3.02 Million SEK | 41.32% |
| 2020 Q1 | 6.1 Million SEK | 183.39% |
| 2019 Q1 | 2.04 Million SEK | 722.27% |
| 2019 Q4 | 2.15 Million SEK | 74.03% |
| 2019 Q2 | 1.37 Million SEK | -32.73% |
| 2019 Q3 | 1.23 Million SEK | -10.02% |
| 2019 FY | 6.8 Million SEK | -27.26% |
| 2018 Q2 | 3.05 Million SEK | -9.98% |
| 2018 Q1 | 3.39 Million SEK | 76.43% |
| 2018 FY | 9.36 Million SEK | 61.63% |
| 2018 Q4 | 248.55 Thousand SEK | -90.65% |
| 2018 Q3 | 2.65 Million SEK | -12.99% |
| 2017 Q3 | 1.61 Million SEK | 12.12% |
| 2017 Q2 | 1.43 Million SEK | 75.19% |
| 2017 Q1 | 821.67 Thousand SEK | -32.59% |
| 2017 FY | 5.79 Million SEK | 10.24% |
| 2017 Q4 | 1.92 Million SEK | 19.24% |
| 2016 Q2 | 1.61 Million SEK | 12.05% |
| 2016 Q4 | 1.21 Million SEK | 25.07% |
| 2016 Q1 | 1.44 Million SEK | 115.75% |
| 2016 FY | 5.25 Million SEK | 426.14% |
| 2016 Q3 | 974.57 Thousand SEK | -39.72% |
| 2015 Q4 | 668.75 Thousand SEK | 484.52% |
| 2015 Q1 | 98.81 Thousand SEK | -59.15% |
| 2015 FY | 998.38 Thousand SEK | 4.62% |
| 2015 Q3 | 114.41 Thousand SEK | -1.71% |
| 2015 Q2 | 116.4 Thousand SEK | 17.8% |
| 2014 FY | 954.33 Thousand SEK | 13.7% |
| 2014 Q4 | 241.89 Thousand SEK | 0.0% |
| 2013 FY | 839.37 Thousand SEK | -61.67% |
| 2012 FY | 2.18 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 99.535% |
| Ziccum AB (publ) | 3.74 Million SEK | 92.794% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.956% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 99.465% |
| Mendus AB (publ) | 28.48 Million SEK | 99.052% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.829% |
| Intervacc AB (publ) | 8.01 Million SEK | 96.631% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 93.827% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.842% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 99.385% |
| Aptahem AB (publ) | 2.63 Million SEK | 89.736% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | 73.913% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -250.649% |
| Fluicell AB (publ) | 3.33 Million SEK | 91.911% |
| Saniona AB (publ) | 16.84 Million SEK | 98.397% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 98.354% |
| Biovica International AB (publ) | 7.29 Million SEK | 96.296% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 77.556% |
| AcouSort AB (publ) | 10.55 Million SEK | 97.441% |
| Xintela AB (publ) | 78 Thousand SEK | -246.154% |
| Abliva AB (publ) | 137 Thousand SEK | -97.08% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 99.531% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 86.594% |
| OncoZenge AB (publ) | 3000.00 SEK | -8900.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -74.194% |
| CombiGene AB (publ) | 5.54 Million SEK | 95.13% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.978% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.984% |
| Corline Biomedical AB | 25.03 Million SEK | 98.921% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 95.245% |
| Isofol Medical AB (publ) | 721 Thousand SEK | 62.552% |
| I-Tech AB | 120.86 Million SEK | 99.777% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.799% |
| Cyxone AB (publ) | 5.14 Million SEK | 94.755% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 96.17% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 97.468% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 97.596% |
| Nanologica AB (publ) | 1.44 Million SEK | 81.289% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -409.434% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.622% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 99.233% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 81.545% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 90.432% |
| Simris Alg AB (publ) | 4.35 Million SEK | 93.799% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -107.692% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.887% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -1073.913% |